Ciprofloxacin in Current Clinical Practice | CMAC

Ciprofloxacin in Current Clinical Practice

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(2):154-162

Journal article


Ciprofloxacin is the most known member of second generation quinolones, which is more active against gram-negative microorganisms and has broad antimicrobial spectrum compared to first generation quinolones. This article presents the main indications for usage of ciprofloxacin and data on resistance of significant pathogens to this fluoroquinolone. The data on clinical and microbiological efficacy of ciprofloxacin as a monotherapy or part of combination antimicrobial regimens, including data from comparative trials, in urinary tract infections (UTI), bacterial prostatitis, enteric infections and intra-abdominal infections (IAI) are considered. Potential for the use of ciprofloxacin in the treatment pelvic inflammatory diseases, skin and soft tissue infections (SSTI), bone and joint infections are also discussed. A focus on the role of ciprofloxacin in the treatment of hospital-acquired lower respiratory tract infections (nosocomial pneumonia) and acute exacerbation of COPD is made.

0 Abstract
0 Crossref citations